Synchron Acquires Equity Stake in ACQUANDAS

Synchron uses a minimally-invasive endovascular procedure that avoids open brain surgery

Synchron, the brain-computer interface (BCI) company developing endovascular technology to restore functionality in patients with motor impairment, today announced the acquisition of an equity stake in ACQUANDAS, a leading technology provider specializing in state-of-the-art high-precision components for the healthcare industry and other industries.

The Stentrode™ Endovascular Electrode Array (Photo: Synchron)
The Stentrode™ Endovascular Electrode Array (Photo: Synchron)

As part of the transaction, Tom Oxley, Synchron’s CEO & Founder, will join the ACQUANDAS Governance Council and Riki Banerjee, Synchron’s CTO, will join as Observer.

“As we pioneer functional endovascular neurotechnology, this investment strengthens our technology innovation and supply chain for our unique product offerings, beginning with brain-computer interfaces,” said Oxley.

“After many years of development in fabrication technology, I am thrilled to welcome Synchron on board as an investor. This major investment will not only strengthen our existing partnership but will also play a pivotal role in expanding our facilities and capabilities. It serves as a testament to the readiness of our fabrication technology and our company for the market,” said CEO & Founder Dr. Rodrigo Lima de Miranda, ACQUANDAS.

ACQUANDAS has established an entirely new generation of shape-memory, flexible metallic components suitable for use as medical devices. Their capability to manufacture miniaturized structures, such as micro-patterned Nitinol thin films, combined with high structure resolution and geometrical complexity, excellent biocompatibility and improved mechanical properties, provides Synchron with a unique product offering in the implantable medical device industry.

More News

The large and lively “HALRIC family” gathered in Lund in February to recap the three amazing years of the project and look ahead to the future. (Photo: HALRIC)
The large and lively “HALRIC family” gathered in Lund in February to recap the three amazing years of the project and look ahead to the future. (Photo: HALRIC)

HALRIC Strengthens Life Science Connections in Northern Europe

After three years, Life Science Nord has issued a positive assessment of the Interreg project HALRIC – Hanseatic Life Science Research Infrastructure Consortium. The project’s ...

Read more …
Dr. Fernando Delgado (CTO), Dr. Michael Hartung (CPO), Alexander Zahn (CEO), and Prof. Dr. Jan Baumbach (CSO) (from left) founded the company in Hamburg in 2025. (Photo: Galagos)
Dr. Fernando Delgado (CTO), Dr. Michael Hartung (CPO), Alexander Zahn (CEO), and Prof. Dr. Jan Baumbach (CSO) (from left) founded the company in Hamburg in 2025. (Photo: Galagos)

#NEWatLSN: Galagos

We are delighted to welcome Galagos as a new member of Life Science Nord e.V.! The founding team answered questions about the company’s initial goals, ...

Read more …
The meetings brought together senior representatives from the European Commission and multiple Member States. (Picture: HALRIC)
The meetings brought together senior representatives from the European Commission and multiple Member States. (Picture: HALRIC)

HALRIC in Brussels

Through direct dialogue with the European Commission and Member States, HALRIC’s Brussels discussions showed how cross-border life science collaboration can unlock efficiency, strengthen European competitiveness, ...

Read more …